特应性皮炎靶向药物治疗进展

New and emerging trends in the targeted treatment for atopic dermatitis

特应性皮炎(atopic dermatitis,AD)是一种常见的慢性炎症性皮肤病,发病机制复杂,临床表型具有异质性。目前AD治疗仍面临极大挑战。基于对其发病机制研究的不断深入,目前发现越来越多新的治疗靶点及候选药物。继白介素(IL)-4Rα抑制剂度普利尤2017年获批以来,IL-13单抗曲罗芦、JAK1/2抑制剂巴瑞替尼先后在欧洲获批用于中重度AD,迄今已有超过70种新型化合物处于研发或临床应用阶段。文章综述了基于不同策略研发的AD靶向药物的最新进展,以期为实现AD精准个体化治疗和长期有效控制提供可能。

Atopic dermatitis(AD)is a common chronic inflammatory skin disease with a complex pathogenesis and different clinical phenotypes.AD treatment continues to be a challenge.With continuous deepening of the pathogenesis,more and more new therapeutic targets and drug candidates have emerged.Since the IL-4Rαinhibitor dupilumab has been approved in 2017,anti-IL-13 inhibitor tralokinumab and JAK1/2 inhibitor baricitinib were succes sively approved for use in moderate and severe AD in Europe.So far,more than 70 new compounds are in development or clinical application.This review summarizes the latest progress of targeted drugs developed based on different strategies,aiming to make it possible to achieve individualized precision treatment and long-term effective control of AD.